Daniel Glaubiger
About
In The Last Decade
Daniel Glaubiger
49 papers receiving 2.4k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Molecular Biology 1.2k
- Oncology 1.0k
- Pulmonary and Respiratory Medicine 436
- Organic Chemistry 254
- Surgery 231
Countries citing papers authored by Daniel Glaubiger
This map shows the geographic impact of Daniel Glaubiger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Glaubiger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Glaubiger more than expected).
Fields of papers citing papers by Daniel Glaubiger
This network shows the impact of papers produced by Daniel Glaubiger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Glaubiger. The network helps show where Daniel Glaubiger may publish in the future.
Co-authorship network of co-authors of Daniel Glaubiger
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Glaubiger. A scholar is included among the top collaborators of Daniel Glaubiger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Glaubiger. Daniel Glaubiger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 58 | |
| 3 | Phase I trial of mitoxantrone in children. | 15 |
| 4 | 20 | |
| 5 | Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. | 166 |
| 6 | Differences in lipid composition of doxorubicin-sensitive and -resistant P388 cells. | 53 |
| 7 | 32 | |
| 8 | 3 | |
| 9 | 9 | |
| 10 | Assessment of in vitro drug sensitivity of human tumor cells using [3H]thymidine incorporation in a modified human tumor stem cell assay. | 34 |
| 11 | 69 | |
| 12 | 15 | |
| 13 | L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. | 124 |
| 14 | 23 | |
| 15 | 79 | |
| 16 | Qualitative and quantitative aspects of intercalator-induced DNA strand breaks breakdown → | 216 |
| 17 | Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule. | 34 |
| 18 | 92 | |
| 19 | 24 | |
| 20 | 25 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.